AKT1 and central nervous system cancer: After treatment with ACT001 for 48 h, the p-PI3K and p-AKT protein levels in glioma cells were significantly reduced compared to the PAI-039 treatment group (a PAI-1 inhibitor) (Fig. 5e, f).